reported that PD-L1 mAbs upregulated PD-L2 expression in macrophages, and when mice were treated with anti-PD-L1 and PD-L2 inhibitors, their survival times were longer than each monotherapy, showing profound synergistic effects and long-term memory of the anti-tumor response. Here, PDCD1LG2 is linked to neoplasm.